Skip to content
Open access

Microglial dectin-1/Clec7a in an alzheimer’s disease model: a double-edged sword across the lifespan

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 35 references
Medicine

TL;DR

Microglial dectin-1 exerts age-dependent effects: beneficial for amyloid pathology in mid-life but detrimental for cognition and anxiety-related behavior in later life, highlighting the need to consider age, the cell types expressing dectin-1, and dectin-1-activating ligands.

Abstract

Introduction Dectin-1, encoded by Clec7a, is highly expressed in disease-associated microglia in Alzheimer’s disease (AD), yet its in vivo function remains largely unknown. Methods We generated Clec7a-floxed mice and conditionally deleted dectin-1 in microglia to determine its effects on pathology and behavior using the 5xFAD mice model. No dectin-1 ligand injection was used. Amyloid pathology, immune phenotypes in the brain, and behavior were examined across disease stages. Results In 6-month (mo) old mice, microglial dectin-1 reduced dense Aβ plaques in the subiculum without detectable behavioral effects. At 9-mo, microglial dectin-1 impaired memory retention and spatial learning, accompanied by an increased diffuse/dense Aβ plaque ratio in the hilus of the dentate gyrus and limited brain infiltration of Ly6Glo neutrophils. At 16-mo, microglial dectin-1 increased freezing behavior suggestive of heightened emotional reactivity. Discussion Microglial dectin-1 exerts age-dependent effects: beneficial for amyloid pathology in mid-life but detrimental for cognition and anxiety-related behavior in later life. These context-specific outcomes highlight the need to consider age, the cell types expressing dectin-1, and dectin-1-activating ligands. Future studies should define the classes of ligands and signaling landscape of microglial dectin-1 across the disease course with the goal of identifying windows where intervention could tilt its function toward sustained neuroprotection.

Read PDF

Similar papers

Review Open access Sep 2026

Border-Associated Macrophage Migrasomes in Alzheimer’s Disease: An Emerging Aβ–Senescence–Microglia Axis?

Alzheimer’s disease (AD) involves not only the neural parenchyma but also brain-border interfaces in which border-associated macrophages (BAMs) regulate amyloid-β (Aβ) handling, vascular function, and immune surveillance. This review focuses on a pathological axis in which persistent vascular Aβ40 and aging-related str...

James Chmiel, M. Kopańska · 0 citations
Open access Sep 2026

Tinosinenside A ameliorates Alzheimer's disease-related pathology in APP/PS1 mice, accompanied by reduced neuroinflammation and altered microglial phenotype-associated marker expression.

Tinospora sinensis (Lour.) Merr. has traditionally been used for its anti-inflammatory properties. Tinosinenside A (Tis A), a major sesquiterpene glycoside isolated from this plant, has shown neuroprotective activity; however, its effects on Alzheimer's disease (AD)-related neuroinflammation remain unclear. This study...

Jing-Jing Wang, Chong Meng, Yong-Yan Xie et al. · 0 citations
Open access Aug 2026

Plasticity of human microglia and brain perivascular macrophages in aging and Alzheimer’s disease

It is shown that a disease-associated microglial subtype, characterized by elevated GPNMB expression and enriched for polygenic AD risk, expands with AD pathology and shows increased phagocytic activity, and MITF is identified as an upstream regulator required to maintain this microglial state.

Donghoon Lee, James M. Vicari, Christian Porras et al. · 1 citation
Aug 2026

An ApoE-Associated Low-Inflammatory Microglial State Emerges After Inflammatory Challenge in Alzheimer's Disease Mice.

A distinct microglial state is identified that provides new insights into the dynamic role of microglia in AD and is associated with the phagocytosis of dystrophic neurites and was recapitulated in vitro using an efferocytosis-based model.

W. Cai, Xiaoli Pan, T. Qian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.